WO1995010975A1 - Dispositif et procede de surveillance et de normalisation de parametres physiologiques - Google Patents

Dispositif et procede de surveillance et de normalisation de parametres physiologiques Download PDF

Info

Publication number
WO1995010975A1
WO1995010975A1 PCT/US1994/011618 US9411618W WO9510975A1 WO 1995010975 A1 WO1995010975 A1 WO 1995010975A1 US 9411618 W US9411618 W US 9411618W WO 9510975 A1 WO9510975 A1 WO 9510975A1
Authority
WO
WIPO (PCT)
Prior art keywords
blood
sensor
normalizing
elongate body
catheter
Prior art date
Application number
PCT/US1994/011618
Other languages
English (en)
Inventor
Michael J. Emery
Original Assignee
Washington Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Washington Research Foundation filed Critical Washington Research Foundation
Priority to AU79780/94A priority Critical patent/AU7978094A/en
Publication of WO1995010975A1 publication Critical patent/WO1995010975A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14542—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring blood gases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14539—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring pH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/1468—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using chemical or electrochemical methods, e.g. by polarographic means
    • A61B5/1473—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using chemical or electrochemical methods, e.g. by polarographic means invasive, e.g. introduced into the body by a catheter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/1495—Calibrating or testing of in-vivo probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
    • A61B5/6846—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive
    • A61B5/6847—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive mounted on an invasive device
    • A61B5/6852—Catheters
    • A61B5/6855—Catheters with a distal curved tip
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
    • A61B5/6846—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive
    • A61B5/6867—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive specially adapted to be attached or implanted in a specific body part
    • A61B5/6876—Blood vessel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
    • A61B5/6846—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive
    • A61B5/6879—Means for maintaining contact with the body
    • A61B5/6884—Clamps or clips
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B2562/00—Details of sensors; Constructional details of sensor housings or probes; Accessories for sensors
    • A61B2562/04—Arrangements of multiple sensors of the same type
    • A61B2562/043—Arrangements of multiple sensors of the same type in a linear array

Definitions

  • the present invention relates generally to devices and methods for monitoring and normalizing physiological parameters, such as blood pH, blood p0 2 , and blood pC0 2 . More specifically, the present invention provides devices and methods for real time monitoring of physiological parameters as well as automated normalization of such parameters.
  • cardiac arrest A common example of exacerbation of an underlying disease by variations of a physiological parameter is cardiac arrest.
  • Cardiac arrest is associated with cardiac arrhythmias, most commonly ventricular fibrillation and asystole.
  • tissue perfusion even during properly performed CPR, is sufficiently low to cause peripheral hypoxia.
  • hypoxia the peripheral cells convert to anaerobic metabolism. This, in turn, results in lactic acid production and systemic acidosis.
  • Cardiac arrhythmias associated with cardiac arrest are exacerbated by acidosis. Gerst et al., Circulation Res.. 19:63-70 (1967). Because acidosis develops during cardiac arrest, conversion of the arrhythmias to a rhythm capable of providing adequate perfusion becomes more difficult as the time of arrest increases. Also, because most cardiac arrests occur away from a medical facility, a period of time elapses
  • sodium bicarbonate may be given during resuscitation. Bleich, New England Journal of Medicine. 321:1345-1346 (1989). Bicarbonate administration is also used during trauma resuscitation. Bau gartner et al., Resuscitation, 20:17-23 (1990) . Generally, sodium bicarbonate is given to patients following a period of arrest. Journal of the American Medical Association, vol. 268, no. 2, October 28, 1992.
  • cardiopulmonary bypass such as performed during open heart surgery, provides a relatively low blood flow to the patient.
  • the low blood flow and attendant hypoperfusion can lead to mild tissue hypoxia and acidosis.
  • Most commonly, the heart is in ventricular fibrillation when warmed following the procedure.
  • the acidosis can impair cardioversion.
  • Real time measurement and correction of acidosis during bypass could facilitate cardioversion following the procedure.
  • Arterial oxygen or carbon dioxide content are physiological parameters which also need to be controlled.
  • Low oxygen tension can lead to tissue hypoxia and damage to organs such as the heart, brain, and kidneys.
  • High inspired and blood oxygen tension can cause pulmonary damage, such as bronchopulmonary dysplasia, and eye injury, such as retrolental fibroplasia, respectively.
  • Alterations in blood carbon dioxide tension can cause pH abnormalities and organ dysfunction as described above.
  • low blood pH may cause neurological symptoms, such as peripheral paresthesias while high blood pH may cause hypersomnolence.
  • a wide variety of other physiological parameters require maintenance in a relatively narrow range. These include blood potassium, blood calcium, blood glucose, and the like. Abnormalities of these electrolytes and other compounds may cause life-threatening cardiac arrhythmias, neurological aberrations, and other undesirable physiological effects.
  • the present invention provides devices for in vivo monitoring and normalizing values of blood parameters, such as blood pH, blood pC0 2 , and blood p0 2 , comprising an in vivo means for sensing the value of the blood parameter, a means for comparing the value of the blood parameter to reference values to produce value differences, and a means for decreasing the magnitude of the value differences.
  • blood parameters such as blood pH, blood pC0 2 , and blood p0 2
  • a plurality of physiological parameter values may be monitored and normalized together or individually.
  • the values may also be displayed in real time or stored for future reference.
  • the present invention comprises an elongate body having a proximal end, a distal end, and a wall surface; a sensor located distally on the elongate body, which sensor is capable of producing a sensor signal representing the value of the physiological parameter; a sensor linkage connecting the sensor to a signal analyzer; and an analyzer linkage connecting the signal analyzer to a means for normalizing the physiological parameter.
  • the elongate body may also contain at least one lumen for administration of physiological normalizers.
  • Methods for in vivo monitoring and normalizing a value of a physiological parameter comprise inserting the distal end of the elongate body of a device as described above into a body lumen and supplying a physiological normalizer to the pump of the device. Ex vivo monitoring and normalization of values of physiological parameters are provided.
  • Fig. 1 illustrates a catheter for monitoring and normalizing pH built in accordance with the principles of the present invention.
  • Fig. 2 illustrates a catheter of the present invention.
  • Fig. 3 illustrates a multi-lumen catheter of the present invention.
  • Fig. 4 illustrates a catheter having two pH sensors constructed in accordance with the principles of the present invention.
  • Fig. 5 illustrates a catheter of the present invention having multiple lumens and multiple sensors.
  • Fig. 6 illustrates a device for in vivo monitoring and normalizing pH according to the principles of the present invention.
  • Fig. 7 illustrates a device for in vivo monitoring and normalizing blood pC0 2 .
  • Fig. 8 illustrates a hard wired circuit for control of an infusion pump.
  • Figs. 9A-9F illustrate different configurations of catheters built in accordance with the principles of the present invention.
  • Fig. 10 illustrates a flow-through device of the present invention.
  • the present invention provides devices and methods for monitoring and normalizing physiological parameters in patients.
  • the devices and methods provide means for real time monitoring and direct and indirect normalizing the parameters.
  • the monitoring can be performed continuously or at regulated intervals.
  • the monitoring and normalization may occur in vivo or ex vivo.
  • in vivo will be understood to mean that the physiological parameter is measured within the body.
  • Sites for measurement within the body include, e.g., blood vessels and airways.
  • ex vivo will be understood to mean that the physiological parameter is measured outside of the body, e.g., measuring blood physiological parameter values in extracorporeal perfusion.
  • physiological parameters may be monitored and normalized by the devices and methods of the present invention.
  • the physiological parameter will be a blood physiological parameter.
  • blood physiological parameters include, e.g., blood pH, blood pC0 2 , blood p0 2 , blood potassium concentration, blood calcium concentration, blood glucose concentration, blood magnesium concentration, and the like.
  • the catheter may also deliver a solution to correct the blood pH.
  • the catheter comprises a tubular elongate body having a proximal end, a distal end, and a wall defining an interior region and an exterior region of the elongate body; a first pH sensor located distally on the exterior wall of the elongate body; and a port located distally on the elongate body, which
  • SUBSTITUTE SHEET (RULE 2 ⁇ ) port provides a fluid opening between' he interior region and the exterior region of the elongate body.
  • monitoring blood pH is meant assessing the value of blood pH.
  • the pH may be assessed continuously or intermittently. When assessed intermittently, the pH will generally be assessed about every 0.1 seconds, although this is not critical and may vary.
  • normalizing blood pH is meant providing a treatment to the patient which acts to directly or indirectly change the acidity of the blood so that the value of the blood pH becomes closer to a predetermined reference value.
  • the reference blood pH value will be 7.40.
  • a higher or lower value may be chosen.
  • persons having chronic obstructive lung disease may retain C0 2 in their blood and normally have a mildly acidic pH.
  • the elongate body will typically be a catheter assembly.
  • the tubular elongate body may be constructed of a variety of materials.
  • the elongate body will comprise a cross-linked polyolefin or halocarbon (usually fluorocarbon) polymer.
  • the elongate body may be formed by extrusion of a suitable thermoplastic polymer by standard methods.
  • Suitable materials for construction of the elongate body include nylons; cross-linked polyolefins such as polypropylenes, polyisoprenes, and polyethylenes; polyvinylchlorides; polyurethanes; halocarbon polymers (particularly fluorocarbons) ; and the like.
  • Such materials display strong plastic memory and may be shaped to a desired diameter and shape when heated above their crystalline melting points.
  • the diameter and length of the elongate body are not critical and may vary. Generally, the outer diameter of the catheter will be about 2 mm. The intended use of the catheter will determine the optimal diameter and length. Persons of skill are familiar with the optimal diameters and lengths for use in different applications of the catheters of the present invention.
  • the catheters may also be preformed to have different curved shapes which may facilitate percutaneous placement of the catheter into different body sites.
  • the distal end of the elongate body will generally be placed within a body lumen while the proximal end of the elongate body will generally remain outside the body.
  • a radiopaque material may be applied to, or contained within, the elongate body to provide a means for fluoroscopic or radiographic localization of the elongate body following placement in a patient.
  • the catheter will be percutaneously inserted through a guide device, such as a Swan-Ganz catheter introducer.
  • the catheter may also be inserted over guide wires.
  • the length of the catheter may vary depending on the desired location of catheter placement and size of the patient. Generally, it will be desirable to monitor the pH in the central venous circulation, i.e., the superior vena cava, inferior vena cava, right atrium, right ventricle, and pulmonary arterial system. Therefore, the length of the catheter will need to be sufficiently long that the distal end of the catheter will reach the central venous circulation from the insertion site, generally about 10 to 75 cm.
  • proximal end it is meant the end of the catheter left outside the body following percutaneous insertion.
  • distal end it is meant the end of the catheter which is in the body following percutaneous insertion.
  • the catheters will generally be tubular.
  • the catheters may have a single lumen or multiple lumens.
  • the lumens may be used to administer a medicament for the correction of blood pH.
  • the lumens may also be used to administer physiological fluids, therapeutic or diagnostic compounds, nutritional compounds, or the like.
  • the lumens will be terminated by a connector which provides a means for making a hermetic connection between the lumen and a fluid source, e.g., a Luer-lock connector.
  • the lumens will terminate in at least one administration port.
  • the administration ports will be located toward the distal end of the catheters.
  • a first pH sensor is located distally on the outer surface of the elongate body.
  • the pH sensor will be capable of in vivo assessment of the pH of the blood.
  • the sensor will generally be an ion sensitive field effect transistor (ISFET) sensor.
  • ISFET ion sensitive field effect transistor
  • a variety of commercially available pH sensors may be employed in the catheters of the present device, including micro-combination probes available from Microelectrodes, Inc., Londonderry, NH.
  • the pH sensor may also include a pH electrode, reference electrode, electrolyte path, and current carrying wires between the electrodes.
  • the catheter may have a first electrolyte lumen containing an electrolyte solution. The first electrolyte lumen terminates distally at a port near the first pH sensor and terminates proximally at the reference electrode. Wires carrying current between the pH electrode and the reference electrode will generally be contained within the wall of catheter.
  • Sensors for other physiological parameters that are suitable for in vivo use are also commercially available. These include, e.g., Na + , K + , Ca ++ , p0 2 , and pC0 2 available from, e.g., Microelectrodes, Inc.
  • flow- through electrodes for measurement of physiological parameters are also available from a variety of suppliers such as Microelectrodes, Inc.
  • such sensors will be ISFET sensors.
  • the administration ports may be located proximal or distal to the pH sensor on the elongate body.
  • the relative placement of the administration port(s) and the pH sensor determines the mode of feedback control for administration of medicaments for normalizing pH.
  • the sensor When the sensor is located upstream from the port in the circulation, the sensor will detect the systemic pH and respond accordingly.
  • the sensor When the sensor is located downstream from the port, the sensor will detect the pH of treated blood and respond accordingly.
  • the catheter may include a second pH sensor located in the elongate body.
  • the second pH sensor may be located proximally or distally to the first pH sensor.
  • the administration port(s) will be located between the first and second pH sensors on the elongate body.
  • the pH at the more distal pH sensor will be higher than the pH at the more proximal pH sensor when the distal end of the catheter is in the internal jugular vein, superior vena cava, right atrium, right ventricle, or pulmonary artery.
  • the relative pH values may vary when the distal end of the catheter is in the right atrium.
  • the blood pH at the more distal pH sensor will be lower than the pH at the more proximal pH sensor when the catheter is introduced through the internal jugular vein and advanced into the inferior vena cava. Therefore, comparison of the pH values provides a means for assessing the placement of the catheter and avoiding misplacement.
  • the catheter may also have a pC0 2 sensor located distally on the elongate body.
  • the pC0 2 sensor provides a measure of the concentration of dissolved carbon dioxide in the blood.
  • Knowledge of the blood pH and the blood pC0 2 provides a means to determine the complete acid base status of the patient and determine whether the patient requires increased ventilation or base correction.
  • the respiratory and metabolic components of acidosis or alkalosis may be assessed by the Henderson-Hasselbach equation:
  • the catheter may also have a balloon located distally on the catheter.
  • a lumen will communicate with the interior of the balloon. Fluids may be introduced into the proximal end of the lumen for inflation of the balloon. Once inflated, the balloon can serve as a means to direct the catheter into the right heart by following the natural blood flow.
  • the physiological parameter may include blood pH, blood pC0 2 , blood p0 2 , blood potassium concentration, blood calcium concentration, or the like.
  • the devices generally comprise an in vivo means for sensing the value of the physiological parameter; a means for comparing the value of the physiological parameter to a reference value to produce a value difference; and a means for decreasing the magnitude of the value difference.
  • the sensing means will generally be electronic. Electronic sensing means may be analog or digital. The sensing means may have a display for direct observation of the physiological parameter value by medical personnel. When the sensor is an electronic analog device, an analog/digital (A/D) converter may be used to convert the signal to digital form. Analog signals may also be amplified, prior to conversion by the A/D converter. Representative pH and pC0 2 sensors are described above.
  • Devices of the present invention also include a means for comparing the physiological parameter value to a reference value.
  • the reference value will be stored in the comparing means.
  • the comparing means will generally be electronic and may operate in analog or digital mode. Often the comparing means will be a microprocessor.
  • the microprocessor may also provide a real time display of the value of the measured physiological parameter to provide medical personnel with clinical data to aid in patient management.
  • the microprocessor may also store selected values of the measured physiological parameter as a means of recording the patient's clinical condition.
  • the reference value When analog signals are compared, the reference value will generally be a voltage range.
  • the comparing means may also be a hard wired circuit as described below.
  • the reference value is preselected and generally be within the normal physiological range of the physiological parameter, e.g., a digital pH range of 7.35-7.45.
  • the clinician may also adjust the reference for appropriate clinical settings. For example, it is generally advisable to keep potassium concentration at low normal or minimally subnormal when coming off cardio-pulmonary bypass. In this instance the clinician could select a reference value which may be just below the normal range. Persons of skill may readily select reference values by methods well known in the medical art.
  • the comparing means will compare the difference between the measured value and the reference value to produce a value difference.
  • the value difference is representative of the variation of the physiological parameter from normal.
  • the value difference may be positive or negative.
  • a means for decreasing the magnitude of the value difference is also included in the present invention.
  • the value difference decreasing means provides a treatment to the patient so that the magnitude of the value difference will move toward zero. In some clinical settings the value difference decreasing means will not actually decrease the magnitude of the value difference, but will stabilize or slow the rate of increase of the magnitude of the value difference. In these instances, it can be seen that while the value decreasing means is not normalizing the value of the physiological parameter, it is stabilizing or slowing the variation of the physiological parameter value.
  • the value decreasing means will vary with the use of the device.
  • the value decreasing means may be an infusion pump which can provide a controlled quantity of a physiological normalizer.
  • physiological normalizer it is meant a substance which will have the effect of normalizing the value of a physiological parameter when administered to a patient.
  • a solution of sodium bicarbonate may be a physiological normalizer which can be administered intravenously to at least partially correct acidosis.
  • a solution of potassium chloride may be used as a physiological normalizer for the correction of hypokalemia.
  • Increased ventilation of the lungs may provide a mixture of gasses (or pure gas) as a physiological normalizer to correct respiratory acidosis.
  • Other examples of physiological normalizers are well known in the art.
  • the infusion pump will typically be a variable speed pump.
  • the speed of the infusion pump will determine the dosage of physiological normalizing solution provided to the patient.
  • the speed may be controlled by altering the voltage provided to the pump or by directly controlling the speed of the pump motor.
  • the value decreasing means may be a gas mixer.
  • altering the fraction of 0 2 in the inspired gas can alter the value of the blood p0 2 and function to normalize the value.
  • Blood pC0 2 may be normalized by varying the respiratory rate or inspiratory tidal volume of patients receiving ventilatory support.
  • the value decreasing means will generally be a means to alter ventilator controls.
  • Some embodiments of the present invention comprise a tubular elongate body having a proximal end, a distal end, and a wall defining an interior region and an exterior region of the elongate body; a first pH sensor located distally on the exterior wall of the elongate body; a port located distally on the elongate body, which port provides a fluid opening between the interior region and the exterior region of the elongate body; a first pH sensor linkage connecting the sensor to a signal analyzer; and an analyzer linkage connecting the signal analyzer to a means for normalizing the pH.
  • a sensor as described above is located distally on the elongate body. By placing the distal end of the elongate body in a desired location in the body, the sensor can be placed relatively precisely.
  • the sensor generates sensor signals which represent the value of the measured physiological parameter.
  • the sensor is connected to a sensor linkage which will carry sensor signals representing the value of the physiological parameter which are generated by the sensor.
  • the sensor signals will be electrical and the sensor linkage will be a wire.
  • the sensor signals may also be light, such as collected reflectance from an 0 2 sensor. In this case the sensor linkage will generally be a fiber optic strand.
  • the sensor linkage may also be a transmitter which does not require physical linkage to transfer sensor signals generated by the sensor.
  • the sensor signals are transferred to a signal analyzer which is connected to the sensor linkage.
  • the signal analyzer receives the sensor signals from the sensor and compares the sensor signals to a pre-selected reference value stored in the signal analyzer.
  • the signal analyzer may also display the sensor signal or store the sensor signal.
  • the signal analyzer will typically be a microprocessor. Alternatively, the signal analyzer may be a hard wired circuit that is constructed to perform the functions of the signal analyzer (e.g., Fig. 8).
  • the pH meter produces a voltage signal that represents the pH of the blood.
  • the voltage signal passes through a buffer amplifier isolating the controller circuitry from the pH meter and amplifying the signal to a usable level.
  • An adjustable voltage signal representing the target pH is produced by a potentiometer.
  • the blood pH signal and the target pH signal are summed by a summing amplifier. When the blood pH signal equals the target pH signal, the output of the summing amplifier equals zero volts. The greater the difference between the blood pH and the target pH, the greater the
  • SUBSTITUTESHEET(RULE28) magnitude of the output of the summing amplifier The voltage signal from the summing amplifier is amplified by an adjustable gain amplifier. Adjustment of the gain of the amplifier allows for adjustment of the speed of the response of the system (ultimately the infusion pump) to a given detected blood pH abnormality.
  • the voltage from the amplifier is converted to a frequency signal by a voltage to frequency converter. Higher voltage output from the amplifier results in conversion to a higher frequency by the signal converter.
  • the frequency signal from the converter is generally a TTL compatible signal (digital) that is passed through a digital buffer for isolation between the controller and a stepping motor that controls the rate of medicament infusion.
  • the signal analyzer produces an analyzer signal which represents the difference between the sensor signal and the reference value.
  • the analyzer signal is transmitted to a means for normalizing the physiological parameter.
  • the analyzer signal provides an input to the normalizing means.
  • the normalizing means will provide a therapeutic response to the patient as described above.
  • the normalizing means will comprise a microprocessor for comparing the signal to a reference value and an infusion pump driven by the microprocessor.
  • the infusion pump will provide an amount of therapeutic medicament determined by the microprocessor.
  • the normalizing means may comprise a hard wired circuit instead of a microprocessor, or a method to control ventilatory parameters, e.g., F i 0 2 , respiratory rate, tidal volume, and the like, instead of an infusion pump.
  • the devices may monitor and normalize both blood pH and blood pC0 2 . These devices include a pH sensor and a pC0 2 sensor which are placed in the patient's body. Generally, the signals produced by the pH sensor and the pC0 2 sensor will be transmitted to a microprocessor. The microprocessor will determine the respiratory and metabolic components of any acid-base disturbances. The microprocessor may then control a variety of infusion pumps which could administer a
  • SUBSTITUTESHEET(RULE28) physiologically acceptable base to correct metabolic acidosis or a physiologically acceptable acid to correct metabolic alkalosis.
  • the microprocessor may also control ventilatory regulators for persons requiring ventilatory support.
  • the microprocessor may adjust the respiratory rate, tidal volume, or both to alter the pC0 2 of the blood and correct any component of respiratory acidosis or alkalosis.
  • the devices of the present invention may also include sensors which monitor the end expiratory pC0 2 of patients on ventilatory support. Such monitoring is useful in a variety of disease states, including chronic obstructive pulmonary disease, drug overdose, post-operative respiratory depression, and the like.
  • the end expiratory pC0 2 closely approximates the arterial blood pC0 2 .
  • the signal from the end expiratory pC0 2 sensor may be transmitted to a microprocessor (or appropriate hard wired device) and provide the information needed for controlling ventilatory parameters, such as Fi0 2 , tidal volume, or respiratory rate.
  • the end expiratory pC0 2 sensor will be placed at the junction of an endotracheal tube (or tracheostomy appliance) and ventilator tubing.
  • the end expiratory pC0 2 sensor may be used in conjunction with intravascular catheters which monitor pH.
  • the signals are generally transmitted to a single microprocessor.
  • the microprocessor may then determine and normalize metabolic and respiratory acid-base disturbances as described above.
  • the present invention also provides devices for ex vivo monitoring and normalizing a value of a physiological parameter in a patient.
  • a wide variety of parameters may be measured, e.g., pH, p0 2 , pC0 2 , potassium concentration, calcium concentration, and the like.
  • These devices are particularly useful in cardio-pulmonary bypass, but may also be used in other therapeutic procedures, such as potassium monitoring during cardio-pulmonary bypass or calcium monitoring during platelet phoresis or dialysis, and the like.
  • the devices useful in ex vivo monitoring will comprise a flow-through tube having a lumen containing a sensor, which sensor is capable of producing a sensor signal representing the value of the physiological parameter; a sensor linkage connecting the sensor to a signal analyzer; and an analyzer linkage connecting the signal analyzer to a means for normalizing the physiological parameter.
  • the components of this embodiment of the present invention are similar to those described above for in vivo monitoring.
  • the device may comprise an elongate body having a proximal end and a distal end; a sensor located distally on the elongate body, which sensor is capable of producing a sensor signal representing the value of the physiological parameter; a sensor linkage connecting the sensor to a signal analyzer; and an analyzer linkage connecting the signal analyzer to a means for directly and indirectly normalizing the physiological parameter.
  • the ex vivo device will be placed in a body fluid, generally blood, from a patient which is being treated ex vivo.
  • the sensor may detect a variety of physiological parameters, such as pH, pC0 2 , calcium concentration, potassium concentration, and the like.
  • the device whether flow-through or an elongate body, will generally be hermetically sealed in the flow path of the body fluid.
  • the sensors will generally be located downstream from the ex vivo therapy device.
  • the body will often be tubular so that the lumen may carry a therapeutic medicament to normalize the physiological parameter.
  • the lumen will terminate distally in at least one port.
  • the port may be located proximal or distal to the sensor.
  • the elongate body may have multiple lumens which may be used to deliver different medicaments.
  • normalization will generally occur by another means, e.g., downstream infusion of a medicament, and the like.
  • the present invention also provides methods for in vivo monitoring and normalizing a value of a physiological blood parameter. The methods generally comprise inserting the distal end of the elongate body of in vivo monitoring devices,
  • a catheter 10 of the claimed invention is demonstrated.
  • the elongate body 12 contains a single lumen 14.
  • the lumen 14 terminates in multiple ports 16.
  • a pH sensor 18 is located distal to the ports 16 on the catheter 10.
  • a wire 20 extends proximally from the pH sensor 18 to an electronic connector 22.
  • the electronic connector 22 provides a means for transmitting signals from the pH sensor 18 to a means for analyzing the signal.
  • the lumen 14 terminates a in fluid connector 24.
  • the fluid connector 24 extends hermetically into the proximal end of the lumen 14.
  • the fluid connector 24 includes a proximal Luer-lock hub for fluidly connecting to an infusion pump.
  • Fig. 2 illustrates a catheter 10 of the present invention in which the ports 16 are located distal to the pH sensor 18.
  • Fig. 3 illustrates a catheter 10 of the present invention having two lumens 14, 15.
  • One lumen 14 terminates distally in multiple ports 16.
  • the other lumen 15 terminates distally in a single port 17.
  • a pH sensor is located between the ports 16 and 17 on the elongate body 12.
  • the lumens terminate proximally in fluid connectors 24 as described above.
  • Fig. 4 illustrates a catheter 10 of the present invention.
  • the catheter has a first pH sensor 18 located distal to the ports 16 on the elongate body 10.
  • a second pH sensor 19 is located proximal to the ports 16 on the elongate body 10.
  • Wires 20, 21 transmit signals from the pH sensors 18, 19 to a signal analyzer.
  • Electronic connectors 22,23 are located at the proximal end of the wires 20, 21.
  • Fig. 5 illustrates a catheter 10 of the present invention.
  • the catheter 10 has a pH sensor 18 and a pC0 2 sensor 25.
  • the catheter 10 also has two lumens 14, 15 for delivery of therapeutic medicaments.
  • Fig. 6 illustrates a device 30 of the present invention.
  • a catheter 32 is in the right heart of a patient 34.
  • a sensor on the catheter 32 transmits signals representing a physiological parameter through wires 36 to a microprocessor 38.
  • the microprocessor 38 analyzes the signal and compares the signal to a reference value.
  • the microprocessor 38 transmits a normalizing signal through an electronic connector 40 to an infusion pump 42.
  • the normalizing signal controls the speed of the infusion pump 42.
  • the infusion pump 42 delivers a normalizing fluid from a reservoir 44 to the patient 34 through a lumen in the catheter 32.
  • the amount of normalizing fluid delivered to the patient 34 is determined by the value of the physiological variable measured in the patient 34.
  • Fig. 7 illustrates a device of the present invention for monitoring and normalizing the blood pC0 2 in a patient 34.
  • a catheter 32 is located in the right heart of the patient 34.
  • the catheter 32 has a distally-located pC0 2 sensor.
  • the sensor produces a signal which is transmitted to a microprocessor 38.
  • the microprocessor 38 analyzes the signal and sends a normalizing signal to a ventilator 50.
  • the normalizing signal controls the respiratory rate of the ventilator 50. Therefore, abnormal changes in the blood pC0 2 of a patient 34 may be normalized.
  • Fig. 8 illustrates a typical hardwired circuit for control of blood pH by a device of the present invention.
  • a pH meter produces a voltage signal 100 that represents the pH of the blood.
  • the voltage signal 100 passes through a buffer amplifier 102 isolating the controller circuitry from the pH meter and amplifying the signal to a usable level.
  • An adjustable voltage signal representing the target pH is produced by a potentiometer 104.
  • the blood pH signal and the target pH signal are summed by a summing amplifier 106.
  • the output of the summing amplifier 106 equals zero volts.
  • the greater the difference between the blood pH and the target pH the greater the magnitude of the output of the summing amplifier 106.
  • the voltage signal from the summing amplifier 106 is amplified by
  • SUBSTITUTESHEET(RULE28) an adjustable gain amplifier 108. Adjustment of the gain of the amplifier 108 allows for adjustment of the speed of the response of the system (ultimately the infusion pump) to a given detected blood pH abnormality.
  • the voltage from the amplifier 108 is converted to a frequency signal by a voltage to frequency converter 110. Higher voltage output from the amplifier 108 results in conversion to a higher frequency by the frequency converter 110.
  • the frequency signal from the converter 110 is generally a TTL compatible signal (digital) that is passed through a digital buffer 112 for isolation between the controller and a stepping motor that controls the rate of medicament infusion.
  • Figs. 9A-9F illustrate different embodiments of the distal portions of elongate bodies of the present invention.
  • Fig. 9A demonstrates a device having one pH sensor 18 located distal to a plurality of ports 16. Such a device senses the pH of treated blood. The device may correct a combined acidosis, detect proper placement by determining the direction of blood flow, and/or allow calculation of cardiac output by a discrete bolus injections of a base or acid.
  • Cardiac outputs may be determined by the following formula:
  • Fig. 9B illustrates a device having a pH sensor 18 located proximal to the a plurality of ports 16. This device detects the pH of untreated blood and may be used to correct combined acidosis.
  • Fig. 9C illustrates a device having a pH sensor 18 and a pC0 2 sensor 25 located distal to a plurality of ports 16. This device may be used to separately correct metabolic and respiratory components of acidosis. Placing the pH sensor 18 and pC0 2 sensor 25 proximal to the ports 16 (Fig. 9D) also allows for separate and simultaneous correction of metabolic and respiratory components of acidosis.
  • Figs. 9E and 9F illustrate devices having pH sensors 18 alone (Fig. 9E) or with pC0 2 sensors 25 (Fig. 9F) located both proximal and distal to the ports 16. These devices provide a means for accurately correcting acidosis even if the catheter is improperly positioned. Cardiac output may be measured continuously by determining the pH difference between the upstream and downstream pH sensors in response to administration of a known amount of acid or base as described above. The device of Fig. 9E having pH sensors 18 alone may correct combined acidosis. The device of Fig. 9F with both pH sensors 18 and pC0 2 sensors 25 may independently correct respiratory and metabolic acidosis components.
  • Fig. 10 illustrates a flow-through device of the present invention for ex vivo use.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pathology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Veterinary Medicine (AREA)
  • Surgery (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Optics & Photonics (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)

Abstract

Dispositifs et procédés de surveillance et de normalisation in vivo et ex vivo de paramètres physiologiques tels que le pH, les taux de sodium, de potassium et de calcium, le pCO2 et le pO2. Les dispositifs utilisés in vivo sont notamment un cathéter allongé (12) portant un senseur physiologique (18) et présentant un orifice (16) par lequel s'effectue la perfusion dans l'organisme d'une solution physiologique en provenance d'un dispositif (42) de normalisation de l'un des paramètres. Lors de l'utilisation, on mesure la valeur du paramètre et on la compare avec une valeur de référence afin d'obtenir une différence. Ensuite, le dispositif de normalisation de la valeur du paramètre provoque une diminution de cette différence. Le dispositif utilisé ex vivo fonctionne de manière analogue, sauf que l'on extrait le sang de l'organisme et on le fait passer par le senseur physiologique (18). Par ailleurs, on peut utiliser plusieurs palpeurs et/ou mesurer plusieurs paramètres.
PCT/US1994/011618 1993-10-18 1994-10-14 Dispositif et procede de surveillance et de normalisation de parametres physiologiques WO1995010975A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU79780/94A AU7978094A (en) 1993-10-18 1994-10-14 Device and method for monitoring and normalizing physiological parameters

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13935593A 1993-10-18 1993-10-18
US08/139,355 1993-10-18

Publications (1)

Publication Number Publication Date
WO1995010975A1 true WO1995010975A1 (fr) 1995-04-27

Family

ID=22486223

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/011618 WO1995010975A1 (fr) 1993-10-18 1994-10-14 Dispositif et procede de surveillance et de normalisation de parametres physiologiques

Country Status (2)

Country Link
AU (1) AU7978094A (fr)
WO (1) WO1995010975A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000004386A2 (fr) * 1998-07-17 2000-01-27 Alertis Medical As Appareil
USRE38203E1 (en) * 1995-08-28 2003-07-22 First Circle Medical, Inc. Extracorporeal whole body hyperthermia using alpha-stat regulation of blood pH and pCO2
WO2005023097A2 (fr) 2003-09-09 2005-03-17 Keimar Inc. Appareil pour verifier des caracteristiques sanguines et sonde associee
WO2014028945A1 (fr) * 2012-08-17 2014-02-20 The Regents Of The University Of California Systèmes, procédés et compositions destinés au traitement amélioré de l'acidose
US20190350443A1 (en) * 2018-05-21 2019-11-21 Mark D. Noar Method For Monitoring A Property Of Tissue Of An Internal Bodily Organ And Adjusting The Tissue Property
EP4091542A1 (fr) * 2021-05-19 2022-11-23 Biosense Webster (Israel) Ltd Cathéter avec mesure de la concentration sanguine en o2/co2

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4151845A (en) * 1977-11-25 1979-05-01 Miles Laboratories, Inc. Blood glucose control apparatus
EP0036171A1 (fr) * 1980-03-10 1981-09-23 Cordis Europa N.V. Capteur électro-chimique à calibration in situ et procédé de fabrication
US4633878A (en) * 1983-04-18 1987-01-06 Guiseppe Bombardieri Device for the automatic insulin or glucose infusion in diabetic subjects, based on the continuous monitoring of the patient's glucose, obtained without blood withdrawal
US4717548A (en) * 1980-06-09 1988-01-05 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Analytically controlled blood perfusion system
US4981470A (en) * 1989-06-21 1991-01-01 Synectics Medical, Inc. Intraesophageal catheter with pH sensor
US5002055A (en) * 1988-04-13 1991-03-26 Mic Medical Instruments Corporation Apparatus for the biofeedback control of body functions

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4151845A (en) * 1977-11-25 1979-05-01 Miles Laboratories, Inc. Blood glucose control apparatus
EP0036171A1 (fr) * 1980-03-10 1981-09-23 Cordis Europa N.V. Capteur électro-chimique à calibration in situ et procédé de fabrication
US4717548A (en) * 1980-06-09 1988-01-05 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Analytically controlled blood perfusion system
US4633878A (en) * 1983-04-18 1987-01-06 Guiseppe Bombardieri Device for the automatic insulin or glucose infusion in diabetic subjects, based on the continuous monitoring of the patient's glucose, obtained without blood withdrawal
US5002055A (en) * 1988-04-13 1991-03-26 Mic Medical Instruments Corporation Apparatus for the biofeedback control of body functions
US4981470A (en) * 1989-06-21 1991-01-01 Synectics Medical, Inc. Intraesophageal catheter with pH sensor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BIO-MED SCIENCES INSTRUMENTATION, SIXTH NATIONAL SYMPOSIUM, 21-23 May 1968, JOHNS et al., "A System for Monitoring Pulmonary Ventilation", pages 119-121. *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE38203E1 (en) * 1995-08-28 2003-07-22 First Circle Medical, Inc. Extracorporeal whole body hyperthermia using alpha-stat regulation of blood pH and pCO2
WO2000004386A2 (fr) * 1998-07-17 2000-01-27 Alertis Medical As Appareil
WO2000004386A3 (fr) * 1998-07-17 2000-04-27 Medinnova Sf Appareil
US6541268B1 (en) 1998-07-17 2003-04-01 Alertis Medical As Carbon dioxide sensor and a method of determining partial pressure of carbon dioxide
JP2007516005A (ja) * 2003-09-09 2007-06-21 ケイマー インコーポレイテッド 血液特性を確定するための器具及びそれと共に使用するためのプローブ
EP1662977A2 (fr) * 2003-09-09 2006-06-07 Keimar Inc. Appareil pour verifier des caracteristiques sanguines et sonde associee
WO2005023097A2 (fr) 2003-09-09 2005-03-17 Keimar Inc. Appareil pour verifier des caracteristiques sanguines et sonde associee
EP1662977A4 (fr) * 2003-09-09 2008-01-23 Keimar Inc Appareil pour verifier des caracteristiques sanguines et sonde associee
US7630747B2 (en) 2003-09-09 2009-12-08 Keimar, Inc. Apparatus for ascertaining blood characteristics and probe for use therewith
WO2014028945A1 (fr) * 2012-08-17 2014-02-20 The Regents Of The University Of California Systèmes, procédés et compositions destinés au traitement amélioré de l'acidose
US20150196708A1 (en) * 2012-08-17 2015-07-16 The Regents Of The University Of California Systems, methods and compositions for improved treatment of acidosis
US20190350443A1 (en) * 2018-05-21 2019-11-21 Mark D. Noar Method For Monitoring A Property Of Tissue Of An Internal Bodily Organ And Adjusting The Tissue Property
EP4091542A1 (fr) * 2021-05-19 2022-11-23 Biosense Webster (Israel) Ltd Cathéter avec mesure de la concentration sanguine en o2/co2

Also Published As

Publication number Publication date
AU7978094A (en) 1995-05-08

Similar Documents

Publication Publication Date Title
US6027498A (en) Control of life support systems
US7527054B2 (en) Apparatus and method for controlling fraction of inspired oxygen
US7302295B2 (en) Method and apparatus for mimicking respiratory sinus arrhythmia with cardiac pacing controlled via external respiration therapy device
US11547784B2 (en) System for CO2 removal
WO2011021978A1 (fr) Contrôle coordonné d'un dispositif de ventilation et d'un dispositif d'assistance pulmonaire
US20220313889A1 (en) Control for Non-Occlusive Blood Pumps
WO1995010975A1 (fr) Dispositif et procede de surveillance et de normalisation de parametres physiologiques
Madsen et al. Pacemaker-induced tachycardia during general anaesthesia: a case report
US20230078164A1 (en) Phrenic nerve stimulation with mechanical ventilation
Malone Physiologic monitors and patient support equipment
Bushman Instrumentation and control in intensive care
JPH0478312B2 (fr)
Robb Physiological changes occurring with positive pressure ventilation: Part one
US20240023873A1 (en) Phrenic nerve integrity and ramped-up burst
CN110382016B (zh) 带有血泵、控制单元和用于传送测量值的仪器的装置
Shen et al. Mechanical Ventilators and Monitors: An Abridged Guide for Engineers
Oximetry 13 420 SECTION 4 Monitoring and life support
Saupe et al. Diastolic time: an important determinant of regional arterial blood flow
Gallagher Taking the pressure off mechanically ventilated patients
Cakar et al. Short term effects of SIMV and PSV on work of breathing by pulmonary monitor CP-100 (Bicore)
Chandrashekar et al. 13 CHAPTER Monitoring and Life Support Equipment
Gertz et al. Studies on pulmonary function in patients during respirator treatment. Diagnostic and prognostic evaluations
Raisis et al. Respiratory and cardiovascular support
Den Dunnen et al. Highly Efficient Jet Ventilation
den Dunnen et al. Pneumatic controlled circulation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE MW SD SZ AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA